Proposed Data Collections Submitted for Public Comment and Recommendations, 55399-55400 [05-18786]
Download as PDF
<![CDATA[
55399
Federal Register / Vol. 70, No. 182 / Wednesday, September 21, 2005 / Notices
E. Process by which the nominating
organization will measure the use of
these products and impact of such use.
6. Topic Selection
Factors that will be considered in the
selection of topics for AHRQ evidence
report and technology assessment topics
include:
A. Burden of disease including
severity, incidence and/or prevalence or
relevance of the organization/financial
topic to the general population and/or
AHRQ’s priority;
B. Controversy or uncertainty about
the topic and availability of scientific
data to support the systematic review
and analysis of the topic;
C. Total costs associated with a
condition, procedure, treatment,
technology, or organization/financial
topic taking into account the number of
people needing such care, the unit cost
of care, and related or indirect costs;
D. Potential for reducing clinically
significant variations in the prevention,
diagnosis, treatment, or management of
a disease or condition; or in changing
the use of a procedure or technology;
informing and improving patient and/or
provider decision making; improving
health outcomes; and/or reducing costs;
E. Relevance to the needs of the
Medicare, Medicaid and other Federal
healthcare programs; and
F. Nominating organization’s plan to
disseminate derivative products,
measure use and impact of these
products on outcomes, or otherwise
incorporate the report into its
managerial or policy decision making.
7. Submission of Nominations
Topics nominations should be
submitted to Kenneth Fink, MD, MGA,
MPH, Director Evidence-based Practice
Centers (EPC) Program, Center for
Outcomes and Evidence, AHRQ, 540
Gaither Road, Rockville, MD 20850.
Electronic submissions to epc@ahrq.gov
are preferred.
Dated: September 12, 2005.
Carolyn M. Clancy,
Director.
[FR Doc. 05–18870 Filed 9–20–05; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–05–04OP]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 371–5983. Send written
comments to CDC, Desk Officer, Human
Resources and Housing Branch by fax to
(202) 395–6974. Written comments
should be received within 30 days of
this notice.
Proposed Project
Delayed Symptoms Associated with
the Convalescent Period of a Dengue
Infection—New—National Center for
Infectious Diseases (NCID), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Dengue is a vector-borne febrile
disease of the tropics transmitted most
often by the mosquito Aedes aegypti.
Symptoms of the acute disease include
fever, headache, rash, retro-orbital pain,
myalgias, arthralgias, vomiting,
abdominal pain and hemorrhagic
manifestations.
A number of symptoms are mentioned
in the medical literature as associated
with the convalescent period after
dengue infection, including depression,
dementia, loss of sensation, paralysis of
lower and upper extremities and larynx,
epilepsy, tremors, manic psychosis,
amnesia, loss of visual acuity, hair loss,
and peeling of skin. The evidence for
these findings has derived mainly from
case series and case reports, but no
analytic study has been conducted to
define the timing, frequency, and
severity of these symptoms, and
quantity the magnitude of the
association between dengue infection
and each of these disorders.
The objective of this study is to
compare mental health disorders and
other delayed complications associated
with dengue infection and
convalescence among study groups. The
study will be conducted in Puerto Rico,
where dengue is endemic, in
collaboration with Dengue Branch of the
Centers for Disease Control and
Prevention. Laboratory positive
confirmed cases of dengue, laboratory
negative suspected dengue cases, and
neighborhood controls will be
prospectively enrolled in the study.
Telephone interviews will be conducted
and information will be collected
prospectively regarding symptoms
experienced during the first five months
after the onset of symptoms of a dengue
infections. There are no costs to the
respondents other than their time. The
estimated annualized burden is 426
hours.
ESTIMATED TOTAL ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Screeners ...............................................................................................................................
Laboratory positive confirmed dengue ..................................................................................
Dengue negative control ........................................................................................................
Neighborhood control ............................................................................................................
VerDate Aug<31>2005
14:40 Sep 20, 2005
Jkt 205001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\21SEN1.SGM
Number of
responses per
respondent
810
200
200
200
21SEN1
2
2
2
2
Average burden
per response
(in hrs.)
1/60
20/60
20/60
20/60
55400
Federal Register / Vol. 70, No. 182 / Wednesday, September 21, 2005 / Notices
Joan Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–18786 Filed 9–20–05; 8:45 am]
Executive Office Building, via fax to
(202) 395–6974. Written comments
should be received within 30 days of
this notice.
BILLING CODE 4163–18–P
Proposed Project
Evaluation of the Poison HELP
Campaign—to Enhance Public
Awareness of the National Poison TollFree Number, Poison Center Access and
Poison Prevention—New—The National
Center for Injury Prevention and Control
(NCIPC).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
(30 Day–05–04KJ)
Background and Brief Description
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 371–5983 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Human
Resources and Housing Branch, New
Every day more than 6,000 calls about
poison emergencies are placed to poison
control centers (PCCs) throughout the
United States. Although PCCs clearly
save lives and reduce healthcare costs,
the system that delivers care and
prevents poisoning is comprised of
more than 131 telephone numbers and
thousands of disjointed local prevention
efforts.
As a result a national media campaign
was launched to establish a national
toll-free helpline entitled Poison Help
(1–800–222–1222) that the general
public, health professionals, and others
can use to access poison emergency
services and prevention information 24
hours a day, seven days a week. The
Poison Help campaign is the only
national and regional media effort to
promote awareness and use of the
national toll-free number. The
prospective audience for the Poison
Help campaign is very broad—any
person at any time is a potential user.
To evaluate the campaign’s current
performance a General Population
Survey will be conducted with 2,500
households in the United States. The
General Population Survey supplies
unique and essential information that
provides CDC and HRSA with data on
variations in awareness and use of the
national toll-free number. These data
will also suggest which campaign
messages about poison prevention or
available PCC services have resonated
most strongly with various audiences.
Results will be used to make
comparisons with future evaluation
activities and to make improvements to
future campaign efforts. There is no cost
to respondents other than their time.
The total annualized estimated burden
hours are 382.
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
Respondents
Screened Households ...........................................................................................................
Survey Respondents .............................................................................................................
Dated: September 15, 2005.
Betsey S. Dunaway,
Acting Reports Clearance Officer, Office of
the Chief Science Centers for Disease Control
and Prevention.
[FR Doc. 05–18790 Filed 9–20–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Government-Owned Inventions:
Availability for Licensing and
Cooperative Research and
Development Agreements (CRADAs)
Centers for Disease Control and
Prevention, Technology Transfer Office,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
SUMMARY: The invention named in this
notice is owned by agencies of the
United States Government and is
VerDate Aug<31>2005
14:40 Sep 20, 2005
Jkt 205001
available for licensing in the United
States (U.S.) in accordance with 35
U.S.C. 207, and is available for
cooperative research and development
agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve
expeditious commercialization of
results of federally funded research and
development. A U.S. non-provisional
patent application and a PCT
application have been filed. National
stage foreign patent applications
claiming priority to the PCT application
are expected to be filed within the
appropriate deadlines to extend market
coverage for U.S. companies and may
also be available for licensing.
ADDRESSES: Licensing and CRADA
information, and information related to
the technology listed below, may be
obtained by writing to Suzanne Seavello
Shope, J.D., Technology Licensing and
Marketing Scientist, Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC), Mailstop
K–79, 4770 Buford Highway, Atlanta,
GA 30341, telephone (770) 488–8613;
facsimile (770) 488–8615; or e-mail
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Number of
responses/respondent
2,940
2,500
Average burden/response
(in hours)
1
1
1/60
8/60
sshope@cdc.gov. A signed Confidential
Disclosure Agreement (available under
Forms at https://www.cdc.gov/tto) will be
required to receive copies of
unpublished patent applications and
other information.
Diagnostics
Development of Real-Time PCR Assay
for Detection of Pneumococcal DNA and
Diagnosis of Pneumococcal Disease
The ability to diagnose pneumococcal
pneumonia is limited by the lack of a
sensitive, specific, and accurate
laboratory assay. Using the PsaA
(pneumococcal protein A) protein gene,
CDC researchers have designed unique
primers and probes and developed a
real-time PCR assay for detection of
pneumococcal DNA in serum and other
sterile site body fluids for the diagnosis
of pneumococcal disease. The PCR
assay provides a tool for accurate
diagnosis by clinicians, and for
determination of the effectiveness
(efficacy) of newly licensed
pneumococcal polysaccharide-conjugate
E:\FR\FM\21SEN1.SGM
21SEN1
]]>Agencies
[Federal Register Volume 70, Number 182 (Wednesday, September 21, 2005)]
[Notices]
[Pages 55399-55400]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-18786]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-05-04OP]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 371-5983. Send written
comments to CDC, Desk Officer, Human Resources and Housing Branch by
fax to (202) 395-6974. Written comments should be received within 30
days of this notice.
Proposed Project
Delayed Symptoms Associated with the Convalescent Period of a
Dengue Infection--New--National Center for Infectious Diseases (NCID),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Dengue is a vector-borne febrile disease of the tropics transmitted
most often by the mosquito Aedes aegypti. Symptoms of the acute disease
include fever, headache, rash, retro-orbital pain, myalgias,
arthralgias, vomiting, abdominal pain and hemorrhagic manifestations.
A number of symptoms are mentioned in the medical literature as
associated with the convalescent period after dengue infection,
including depression, dementia, loss of sensation, paralysis of lower
and upper extremities and larynx, epilepsy, tremors, manic psychosis,
amnesia, loss of visual acuity, hair loss, and peeling of skin. The
evidence for these findings has derived mainly from case series and
case reports, but no analytic study has been conducted to define the
timing, frequency, and severity of these symptoms, and quantity the
magnitude of the association between dengue infection and each of these
disorders.
The objective of this study is to compare mental health disorders
and other delayed complications associated with dengue infection and
convalescence among study groups. The study will be conducted in Puerto
Rico, where dengue is endemic, in collaboration with Dengue Branch of
the Centers for Disease Control and Prevention. Laboratory positive
confirmed cases of dengue, laboratory negative suspected dengue cases,
and neighborhood controls will be prospectively enrolled in the study.
Telephone interviews will be conducted and information will be
collected prospectively regarding symptoms experienced during the first
five months after the onset of symptoms of a dengue infections. There
are no costs to the respondents other than their time. The estimated
annualized burden is 426 hours.
Estimated Total Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response
respondents respondent (in hrs.)
----------------------------------------------------------------------------------------------------------------
Screeners.................................................... 810 2 1/60
Laboratory positive confirmed dengue......................... 200 2 20/60
Dengue negative control...................................... 200 2 20/60
Neighborhood control......................................... 200 2 20/60
----------------------------------------------------------------------------------------------------------------
[[Page 55400]]
Joan Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 05-18786 Filed 9-20-05; 8:45 am]
BILLING CODE 4163-18-P
